Trial Profile
A Study to Evaluate the Effects of Natalizumab on Cognitive Functions in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Dec 2015 New trial record